Stone Pharmaceuticals Group: Meloxicam Injection Approved for Drug Registration Permit.

On the morning of June 23, CSPC Pharmaceutical Group announced on the Hong Kong Stock Exchange that the group's developed Meloxicam Injection has obtained a drug registration approval from the Chinese National Medical Products Administration. The approved indication for this time is "for the treatment of moderate to severe pain in adults", making it the first intravenous nanocrystal product approved in China.